Working to provide information, support and access to established, new or innovative treatments for Atrial Fibrillation (AF)
INTERNATIONAL HEART RHYTHM CONGRESS CALLS FOR URGENT ACTION TO PREVENT THOUSANDS OF UNNECESSARY DEATHS FROM ARRHYTHMIAS..
Over 3,000 heart rhythm specialists and healthcare professionals from around the world are arriving in Birmingham for the annual Heart Rhythm Congress (HRC), starting on Sunday (1-4 October), the UK’s largest educational congress devoted solely to arrhythmias (heart rhythm disorders).
ARRHYTHMIA ALLIANCE WELCOMES NHS CALL TO PROVIDE TESTS TO IDENTIFY PEOPLE WITH UNDIAGNOSED HEART RHYTHM DISORDERS
Local health authorities do not mandate or commission manual pulse rhythm checks recommended as part of NHS health check service
Interview with Trudie Lobban MBE, Founder & Trustee of Arrhythmia Alliance
Arrhythmia Alliance is a coalition of charities, patient groups, patients, carers, healthcare professionals, policy-makers, politicians, allied professionals and all those involved in the care of or affected by cardiac arrhythmias. Arrhythmia Alliance works in collaboration to improve diagnosis, treatment and quality of life for all those suffering with arrhythmias.
Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE)
Atrial fibrillation (AF) is the most common cardiac arrhythmia, occurring in 1–2% of the general population. Its prevalence varies between continents and ethnicity, but the estimated number of patients with AF worldwide might be between 30 and 100 million.1 This prevalence is expected to increase significantly in the next 30–50 years due to an ageing population, and increasing risk factors to develop AF, including arterial hypertension and diabetes.2–5 In all populations studied, both prevalence and incidence are higher in men than in women and increase with age.6
WORLD HEART RHYTHM WEEK 5-11 JUNE 2017 TAKE THE PULSE CHECK CHALLENGE – IT COULD SAVE YOUR LIFE
HIGH RISK AF PATIENTS DENIED ACCESS TO LIFE-SAVING TREATMENT
New patient survey results show 80% of AF patients say ‘YES’ to the freedom that INR self-monitoring gives them
The purpose of this survey was to help discover patient thoughts and opinions about INR self-monitoring versus clinic visits. Several trials have demonstrated that patient self-monitoring (PSM) by those on long term warfarin significantly improves time in therapeutic range (TTR) and leads to better management outcomes.
Arrhythmia Alliance places 3000th Public Access Defibrillator on World Restart the Heart Day
“AEDs must be as commonplace as fire extinguishers and smoke alarms if we are to dramatically reduce the number of deaths from sudden cardiac arrest in the UK.”
New real-world analysis reports lower risk of major bleeding with dabigatran compared to rivaroxaban in stroke prevention
Ingelheim, Germany, 13.October 2016 – A large observational study by researchers from the U.S. FDA has found that dabigatran (150 mg twice daily) was associated with lower rates of intracranial haemorrhage and major extracranial bleeding, including major gastrointestinal bleeding than rivaroxaban (20 mg once daily) in patients with atrial fibrillation (AF). The study is the largest observational study to-date comparing the two drugs, and analysed data from over 118,000 AF patients. Based on the data published in JAMA Internal Medicine, the accompanying Editor’s Note written by Parks and Redberg suggests that physicians should “prescribe dabigatran over rivaroxaban for patients with atrial fibrillation.”